JavaScript NENÍ povolen !

* Zobrazit nápovědu

144 záznamů v Medvik Filtry

Abstrakt

Kohoutek, M
Autor Kohoutek, M OKBMI Nemocnice Jihlava

Klinická biochemie a metabolismus. 2018 ; 26 (2) : 102. (49. celostátní sjezd biochemických laborantů České společnosti klinické biochemie ČLS JEP, BIOLAB 2018, Jihlava, 27.5. - 29. 5. 2018)

Klin. biochem. metab.
ISSN 1210-7921
Medvik
Zdroj

Publikační typ
abstrakt z konference MeSH

Článek

Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis

Journal of the European Academy of Dermatology and Venereology. 2013 ; 27 (4) : 514-9.

J Eur Acad Dermatol Venerol
ISSN 1468-3083
Medvik
Zdroj

BACKGROUND: Targeted oncology therapy with inhibitors of epidermal growth factor receptor is associated with numerous cutaneous side effects. Acneiform eruptions are the most frequent skin toxicities reported. They may lead to impairment of patients' quality of life and sometimes may even become severe enough to necessitate the interruption or cessation of therapy. OBJECTIVE: To assess the possible effect of topical phytomenadione (vitamin K1 ) pre-treatment in diminishing the extent and severity of acne-like follicular rash associated with epidermal growth factor receptor inhibitor therapy. METHODS: A series of 20 patients with colorectal cancer or head and neck cancer were pre-treated with phytomenadione cream (0.05% in seven patients and 0.1% in 13 patients), starting morning before the first infusion of cetuximab or panitumumab, and followed up for the development of therapy-associated folliculitis. The cream was prepared from phytomenadione solution added to a hydrophilic cream base, oil in water, to obtain the concentration of 0.05% or 0.1%. RESULTS: Majority of patients (15 out of 20, 75%) pre-treated with phytomenadione cream experienced only mild, grade I acneiform eruptions. Five patients (25%) had grade II rash, which included two of seven patients pre-treated with 0.05% phytomenadione cream and three of 13 patients who used 0.1% phytomenadione cream. Topical phytomenadione cream was well tolerated and no abnormalities in blood coagulation were observed. CONCLUSIONS: Topical pre-treatment with phytomenadione cream might become useful in epidermal growth factor inhibitor-associated acneiform eruptions.

Článek

Cetuximab-induced cutaneous toxicity

Journal of the European Academy of Dermatology and Venereology. 2010 ; 24 (6) : 692-6.

J Eur Acad Dermatol Venerol
ISSN 1468-3083
Medvik
Zdroj

BACKGROUND: Epidermal growth factor receptor inhibitors are recently utilized by oncologists in advanced cases of certain malignancies. However, these agents are associated with numerous cutaneous adverse reactions. OBJECTIVE: To systematically review the cutaneous toxicity of cetuximab-treated patients. METHODS: An analysis of a series of 24 patients (20 men and 4 women) treated with cetuximab (12 patients with head and neck cancer and 12 patients with colorectal cancer) was performed with respect to relevant clinical characteristics. RESULTS: A total of 22 patients (91.7%) developed pustular or maculopapular follicular eruption, often referred to as acneiform rash. One patient (4.2%) developed paronychia in the course of cetuximab therapy. All patients with head and neck cancer had a combination treatment with radiotherapy and experienced radiation dermatitis accompanied by skin xerosis. Anaphylactic reaction was observed in three patients (12.5%). CONCLUSIONS: The most frequent cutaneous side effect reported in this series was acneiform eruption. The authors observed that all women with acneiform rash had only limited facial involvement, whereas all but one man experienced more widespread lesions of the face, the back and the chest. We found no association between the extent and severity of cutaneous eruptions (grade 1 vs. grade 2) and patients' response to therapy.